Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 0.69 |
| ▸ | TNKS | O95271 | 15/20 | 0.69 |
| ▸ | PARP2 | Q9UGN5 | 14/20 | 0.69 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16432069 | 0.92 | PARP1 (0.70) | PARP1TNKSPARP2TNKS2 | |
| SCHEMBL16432362 | 0.89 | PARP1 (0.65) | PARP1TNKSPARP2TNKS2 | |
| SCHEMBL16432166 | 0.89 | PARP1 (0.69) | PARP1TNKSPARP2TNKS2 | |
| SCHEMBL16432435 | 0.87 | TNKS (0.76) | PARP1TNKSPARP2TNKS2 | |
| SCHEMBL16432197 | 0.86 | PARP1 (0.72) | PARP1TNKSPARP2TNKS2 | |
| SCHEMBL16432595 | 0.86 | TNKS (0.64) | PARP1TNKSPARP2TNKS2 | |
| SCHEMBL16442381 | 0.83 | PARP1 (0.61) | PARP1TNKSPARP2 | |
| SCHEMBL16432040 | 0.83 | TNKS (0.75) | PARP1TNKSPARP2TNKS2 | |
| SCHEMBL16432485 | 0.83 | PARP1 (0.68) | PARP1TNKSPARP2TNKS2 | |
| SCHEMBL16432593 | 0.83 | TNKS (0.56) | PARP1TNKSPARP2TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9901577-B2 | Oxoquinazolinyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9901577-B2 | Oxoquinazolinyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-20160184310-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-06-30 | — | — | US | disclosed |
| US-20160184310-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184310-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | TANK, IRAK3, TNKS | PARP1 76/4885TNKS 3/4885PARP2 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.